Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Adaptive Design returned 36 record(s)
|
|
Sunday, 07/29/2018
|
Dose Selection Using Nonlinear Mixed-Effect Model Averaging Approaches in Conjunction with Adaptive Optimal Design Techniques
Andrew Hooker, Uppsala Universitet
2:45 PM
|
A Non-Response and Measurement Error Analysis for the National Survey of College Graduates
Kayla Varela, U.S. Census Bureau; Allison Zotti, U.S. Census Bureau; Kevin Tolliver, U.S. Census Bureau; Amanda Nagle, U.S. Census Bureau
4:05 PM
|
Implementation of Adaptive Design on the Medicare Current Beneficiary Survey
Christopher Ward, NORC at the University of Chicago; Felicia LeClere, NORC at the University of Chicago; Kari Carris, NORC at the University of Chicago; Stephen Cohen, NORC at the University of Chicago; Dean Resnick, NORC; Micah Sjoblom, NORC at the University of Chicago; Jennifer Vanicek, NORC at the University of Chicago; Ying Li, NORC at the University of Chicago
4:20 PM
|
Adaptive Design in the National Immunization Survey-Teen Provider Record Check Phase
Xian Tao, NORC at the University of Chicago; Megha Revanam, NORC at the University of Chicago; Benjamin Skalland, NORC at the University of Chicago; Kirk Wolter, NORC at the University of Chicago; David Yankey, Centers for Disease Control and Prevention; Zhen Zhao, CDC; Kennon Copeland, NORC at the University of Chicago
4:35 PM
|
An Approach to Predict Final Yield Among Interim Cases
Rui Jiao, Westat; Andrea Piesse, Westat
5:20 PM
|
|
Monday, 07/30/2018
|
Basket Trial Design Using Bayesian Model Averaging
Matthew Psioda, University of North Carolina; Jiawei Xu, University of North Carolina; Qi Jiang, Amgen; Chunlei Ke, Biogen; Zhao Yang, Amgen Inc; Joseph G Ibrahim, University of North Carolina Chapel Hill
8:35 AM
|
Formulation of Data Monitoring Committee Recommendations for Adaptive Design Clinical Trials
Navneet Hakhu, Axio Research
8:50 AM
|
A Bayesian Logistic Model with Covariate to Identify Optimal Dose for Heterogeneous Population in Phase I Oncology Trial
Xin Wei, Celgene Corporation; Michael Branson, celgene corporation
8:50 AM
|
A Novel Framework for Bayesian Response-Adaptive Randomization
Jian Zhu, Takeda; Ina Jazic, Harvard University; Yi Liu, Takeda Pharmaceuticals
9:50 AM
|
A Parametric Multiple Comparison Procedure for Clinical Trials with Planned Evaluation of Treatment Effect in Pre-Defined Subgroups and Interim Analyzes
Liang Fang, MyoKardia; Ron Yu, Gilead Sciences, Inc.; Zhishen Ye, Gilead Sciences; Neby Bekele, Gilead Sciences; Ming Lin, Gilead Sciences
3:05 PM
|
|
Tuesday, 07/31/2018
|
A Bayesian Adaptive Design in Cancer Phase I/II Trials with Drug Combinations Using Escalation with Overdose Control (EWOC) and Adaptive Randomization
Sungjin Kim, Cedars-Sinai Medical Center; José L. Jiménez, Politecnico di Torino; Mourad Tighiouart, Cedars-Sinai Medical Center
|
Adaptive Design: Challenges in Practice
Michael Yang, NORC
|
Sample Size in Adaptive Design with Treatment Selection
Zejiang Yang, Syneos Health
|
Bayesian Methods in Real-World Evidence for Medicinal Product Development: Can Prior Distributions Provide a Platform for Creating Real-World Evidence?
John Loewy, Dataforethought
|
STEPDOWN TESTING PROCEDURES for DOSE FINDING STUDY with ADAPTIVE DESIGN
Gang Jia, Merck & Co.
|
Data-Driven Biomarker Evaluation in Adaptive Designs Using SIDES
Ilya Lipkovich, IQVIA; Alex Dmitrienko, Mediana Inc
8:35 AM
|
STEPDOWN TESTING PROCEDURES for DOSE FINDING STUDY with ADAPTIVE DESIGN
Gang Jia, Merck & Co.
8:55 AM
|
A Confirmatory Basket Trial Design for Multiple Tumor Types Based on Conditional Power
Huiling Li; Jianming Wang, Celgene Corporation; Yeongjin Gwon, University of Connecticut; Xiaolong Luo, Celgene Corporation
9:05 AM
|
Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial
Rui Tang, Shire; Xiaoye Ma, University of Minnesota; Hui Yang, Amgen Inc.
11:50 AM
|
|
Wednesday, 08/01/2018
|
Successful Implementation of Bayesian Adaptive Designs in Medical Device Clinical Studies
Zengri Wang
|
Practical Guidelines and User-Friendly Software for Bayesian Adaptive Designs
J. Jack Lee, Univ of Texas-M D Anderson Cancer Center
|
Bayesian Adaptive Design of Phase 2 Dose-Finding Study
Tanya Granston, CTI BioPharma Corp.; Huafeng Zhou, CTI BioPharma Corp.; Lixia Wang, CTI BioPharma Corp.
|
A Case Study of Adaptive Seamless Design with Subpopulation Selection in Oncology
Rui Qin, Janssen Pharmaceutical R&D
8:55 AM
|
Bayesian Blinded Sample Size Adjustment for Risk Differences
Andrew Hartley, PPD, Inc.
9:15 AM
|
A Model-Based Approach for Simulating Adaptive Clinical Studies with Surrogate Endpoints Used for Interim Decision-Making
Xiaotian Chen, AbbVie; Alan Hartford, AbbVie Inc; Mei Li, AbbVie; Jun Zhao, AbbVie
9:20 AM
|
Bayesian Adaptive Design of Phase 2 Dose-Finding Study
Tanya Granston, CTI BioPharma Corp.; Huafeng Zhou, CTI BioPharma Corp.; Lixia Wang, CTI BioPharma Corp.
9:45 AM
|
Evaluating the Statistical Properties of Bayesian Basket Trial Designs
Kristen May Cunanan, Memorial Sloan Kettering Cancer Center; Alexia Iasonos, Memorial Sloan Kettering Cancer Center; Ronglai Shen, Memorial Sloan-Kettering Cancer Center; Colin B Begg, Memorial Sloan Kettering Cancer Center; Mithat Gonen, Memorial Sloan Kettering Cancer Center
10:35 AM
|
Bayesian Uncertainty Directed Trial Designs
Lorenzo Trippa, Harvard
11:05 AM
|
On Randomized Controlled Trials with Integrated Real World Evidence for Drug Development in Rare Diseases
Qing Liu, Amicus Therapeutics, Inc
11:15 AM
|
Adaptive Dose Finding in Oncology Phase I-II Studies with Consideration of Tolerability and Efficacy
Rachael Liu, Takeda Pharmaceuticals ; Ling Wang, Takeda; David Sinclair, Google; Jianchang Lin, Takeda Pharmaceuticals
11:35 AM
|
Dependencies in Binary Regression Data Generated by Informed Sequential Dose Allocation
Nancy Flournoy, University of Missouri; Assaf Oron, Instutue for Disease Modeling
2:25 PM
|
|
Thursday, 08/02/2018
|
Extension to Signature Design
Xiting Yang, Food and Drug Administration
9:20 AM
|
Selecting a Sample from a Changing Frame of Program Beneficiaries
Eric Grau, Mathematica Policy Research
9:35 AM
|
A Bayesian Adaptive Phase 1/2 Design of Cisplatin and Cabazitaxel in Prostate Cancer with Visceral Metastasis
Mourad Tighiouart, Cedars-Sinai Medical Center
10:35 AM
|
Practical Considerations of Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials
Jianchang Lin, Takeda Pharmaceuticals; Rachael Liu, Takeda Pharmaceuticals ; Veronica Bunn, Florida State University
11:20 AM
|
BOIN-ET: Bayesian Optimal Interval Design for Dose Finding Based on Both Efficacy and Toxicity Outcomes
Kentaro Takeda, Astellas Pharma Global Development, Inc.; Masataka Taguri, Yokohama City University; Satoshi Morita, Kyoto University
12:05 PM
|
|
|
